Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
VIMPAT (UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia)
Product name
VIMPAT
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
lacosamide
Registration type
EOI
Indication
VIMPAT (solution for inejction, oral solution, tablet) is now also indicated as add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older